Figure 2 Projected Total Costs During Bridging Period LOWER COSTS ASSOCIATED WITH HOME DISCHARGE OF BRIDGE-TO-TRANSPLANT PATIENTS USING THE TLC-II PORTABLE.

Slides:



Advertisements
Similar presentations
Regionalization of health care Matching supply to demand Matching supply to demand Maximizing resource allocation Maximizing resource allocation National.
Advertisements

100% Total Protection Plus 100% Total Protection Plus.
C & C Benefits Group, LLC In Business Since 1977 Specializing In Guaranteed Acceptance Health Plans Licensed Health Agent In 30 States Required by law.
Chapter 5 Mathematics of Finance.
Puzzle A Puzzle B. Replace ? with + – x or ÷ so the results of each of the and 5-number calculations are 15 when working one step at a time from.
4 CHAPTER Elasticity.
1 Unit F: Effectively Managing Business Transactions Lesson 1: Understanding Business Expenses.
Cost-Effectiveness of Left Ventricular Assist Devices (LVADs) as Permanent Implants for End-Stage Heart Failure David Samson Blue Cross and Blue Shield.
The Impact of Drug Benefit Caps Geoffrey Joyce, PhD.
TABLE OF CONTENTS CHAPTER 1.0: Trends in the Overall Health Care Market Chart 1.1: Total National Health Expenditures, 1980 – 2005 Chart 1.2: Percent Change.
Chartbook 2005 Utilization and Volume Chapter 3: Utilization and Volume.
Chapter 5: Workforce. Chartbook 2003 Physician Workforce After dropping slightly in 1999, the number of active physicians per thousand population rose.
Chapter 3: Utilization and Volume. 26 Chartbook 2000 Community hospital acute care admissions declined 15 percent between 1980 and 1994 and then began.
THE COMMONWEALTH FUND Figure 1. Health Insurance Coverage and Uninsured Trends Data: Analysis of the U.S. Census Bureau, Current Population Survey Annual.
Funding Alternatives for Long Term Care. Costs of Long Term Care Home Care $0 - $500 per day Adult Day Care $50 per day and up Facility Care $3,000 -
Magnesium Diboride Program Hyper Tech Research Inc. Mike Tomsic Magnesium Diboride Workshop April 2003 Research Partners: Ohio State University-LASM National.
6 November 2003 Multiprofessional Working – a new orthopaedic model Dr Sarah Schofield Southampton Health Economy.
Corporate Estimated Taxes Code Section 6655 By: Stephanie Shields.
Mathematics of Compound Interest
Chapter 11 Cash Flow Estimation
What is Inventory? Definition--The stock of any item or resource used in an organization Raw materials Finished products Component parts Supplies Work.
Inventory BA 339 Mellie Pullman
Chapter 5 Appendix Indifference Curves
Key Concepts and Skills
Introduction This chapter examines one of the most basic planning tools available to managers: cost-volume-profit analysis. Cost-volume-profit analysis.
Chapter 3 Supply and Demand. Chapter Objectives Define and explain demand in a product or service market Define and explain supply Determine the equilibrium.
BACKGROUND Ventricular assist devices (VADs) are a proven therapy as bridge-to-cardiac transplantation in Class IIIB and Class IV heart failure patients.
4 Elasticity Notes and teaching tips: 9, 27, 42, 43, 49, and 63.
What is Inflation? Inflation is rising general level of prices
Chapter 16 Goodness-of-Fit Tests and Contingency Tables
Cost-Volume-Profit Relationships
Time Value of Money Time value of money: $1 received today is not the same as $1 received in the future. How do we equate cash flows received or paid at.
Inflation Unit Chapter 2 26
 What is an eating disorder  What are the types of eating disorders  What are the treatment options  What is an RD’s role in eating disorders.
US cost-effectiveness of simvastatin in 20,536 people at different levels of vascular disease risk: randomised placebo-controlled trial UK Medical Research.
Activity-Based Costing and Management Management Accounting: The Cornerstone for Business Decisions Copyright ©2006 by South-Western, a division of Thomson.
Tudor House & Rectory Road Medical Practice Pathfinder Harry Longman Nicci Iacovou
End Simplify A. 13B. 147 C. 17D – 2(5)+7.
Risk, Return, and the Capital Asset Pricing Model
Rate of Return Multiple Alternatives Lecture slides to accompany
Case 11: If The Coat Fits Wear It
By: Joseph DeRose Profession: Fitness Specialist at Magna Health Insurance Target Audience: Bob Drysdale, CEO, Magna Health Insurance.
13. Healthcare Sector Costs Payments and revenue received by physicians and healthcare entities represent the cost of business for the government, insurance.
The role of insurance in health care, part 2 Today: More on moral hazard Other issues in insurance Problems with insurance.
Equipoise Does Not Exist for REVIVE IT Andrew Boyle, MD Heart and Vascular Center Director, Florida Chairman of Cardiology Medical Director of Heart Failure,
Hospitalizations for Severe Sepsis Among Elderly Medicare Beneficiaries William Buczko, Ph.D. Research Analyst Centers for Medicare & Medicaid Services.
Trends In Health Care Industry KNH 413. Difficult questions What is health insurance? What is health care versus health insurance? Is one or both a right.
Out-of-pocket healthcare expenditures for cancer patients in the United States: Findings from the Medical Expenditure Panel Survey Lisa M. Lines, MPH 1,2.
Health Insurance HEALTH INSURANCE COVERAGE Hospital insurance pays for most of your charges if you are hospitalized with and illness or injury.
Introduction to Ventricular Assist Device (VAD)
Transition to Next Level of Care Management of Patient with Ventricular Assist Device Hospital Home Transition.
Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients Assessment.
Health Insurance and the Demand for Medical Care: Evidence from a Randomized Experiment Willard G. Manning et al. (1987) June 1, 2007 Willard G.
Top Ten things you need to know… About VAD’s Kim Byrum Chappell Mechanical Assist Coordinator.
THE EFFECT OF A HEART ASSIST DEVICE CLINICAL STUDY ON HOSPITAL REFERRALS AND REVENUES Background From May 1998 to July 2001, chronic end-stage heart failure.
Ventricular Assist Device: Intervals for dressing changes By. Megan Giska.
Presented at The 129th Annual Meeting of the American Public Health Association Atlanta, GA, October 21–25, 2001 Presented by Amanda A. Honeycutt Linda.
Figure 1 Patients outside of target international normalized ratio range by time point and management strategy. All values are expressed as percentages.
PCI related in-hospital mortality based on race and gender in the USA
Evaluating Policies in Cardiovascular Medicine
Fifth INTERMACS annual report: Risk factor analysis from more than 6,000 mechanical circulatory support patients  James K. Kirklin, MD, David C. Naftel,
Monaldi Hospital -Azienda Ospedaliera dei Colli - Naples (IT)
Bart S. Ferket, MD, PhD, Jonathan M
INOVATE-HF Trial design: Patients with heart failure (HF) were randomized to device implant for vagus nerve stimulation (n = 436) versus optimal medical.
Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.
CHAMPION Trial design: Patients with recent hospitalization for heart failure were implanted with a pulmonary artery pressure monitor and randomized so.
Jerry D. Estep et al. JCHF 2013;1:
Willard G. Manning et al. (1987) June 1, 2007 Willard G.
Survival of subjects listed for heart transplantation with different spirometric ventilatory patterns. Survival of subjects listed for heart transplantation.
Survival of subjects listed for heart transplantation with and without spirometry. Survival of subjects listed for heart transplantation with and without.
Presentation transcript:

Figure 2 Projected Total Costs During Bridging Period LOWER COSTS ASSOCIATED WITH HOME DISCHARGE OF BRIDGE-TO-TRANSPLANT PATIENTS USING THE TLC-II PORTABLE DRIVER BACKGROUND Approximately 2,400 patients receive heart transplants each year. Of those 2,400 patients, about 15 to 20 percent are first implanted with a ventricular assist device (VAD) while awaiting a donor heart. In November 2003, the TLC-II Portable Driver received FDA approval for home use in support of bridge-to-transplant (BTT) patients implanted with the Thoratec VAD System. Before the availability of the TLC-II Portable Driver, patients were confined to an inpatient stay while awaiting heart transplantation, averaging 108 days as previously determined by DeRose 1 et al. VAD Implantation Continued Hospital Inpatient Stay Discharge to Home TLC-II Purchase TLC-II Rental Heart Transplantation Our objective was to compare the medical costs incurred during home discharge supported by a TLC-II Portable Driver versus continued hospital inpatient stay, which is the current standard of care for a BTT patient. METHODS In order to design a model to project medical costs during the bridging period for a BTT, a literature review was undertaken. The following were determined, based on data from the study by Morales 2 et al, on the associated cost of VADs, the Thoratec equipment price listing, and industry experience: Estimated inpatient cost per day Estimated home discharge cost per day Hospital acquisition cost for two TLC-II Portable Drivers as required for FDA compliance Estimated TLC-II Portable Driver rental cost per month The model was setup using a spreadsheet to calculate the costs associated with a continued hospital inpatient stay, discharge home with the purchase of two TLC-II Portable Drivers, and discharge home with the rental of two TLC-II Portable Drivers over a range of 0 to 150 days. Equations for each cost scenario: Continued hospital inpatient stay: [Cost = Inpatient Cost per Day x Days] Discharge home with purchase of two TLC-II Portable Drivers: [Cost = (Home discharge cost per day x Days) + TLC-II acquisition cost] Discharge home with rental of two TLC-II Portable Drivers: [Cost = (Home discharge cost per day x Days) + TLC-II rental cost per month] Scatter line graphs were plotted using the equations to compare: The cost of continued inpatient stay vs. home discharge with purchase of the TLC-II Portable Driver The cost of continued inpatient stay vs. home discharge with rental of the TLC-II Portable Driver From the literature review, it was determined that the costs during the bridging period for continued inpatient stay were made up of general floor, medication, laboratory tests, dressing supplies, and professional fees. The daily costs for these components were $1,604, $3, $10, $5, and $50 respectively. The estimated daily inpatient cost was determined to be $1,672 per day. Table 1 Medical Costs Associated with TLC-II Driver Expenses Continuous Hospital Stay Discharge Home w/ TLC-II Purchase Discharge Home w/ TLC-II Rental General Floor$1,604$0 Medication$3 Laboratory Tests $10 Dressing Supplies $5 Professional Fees $50$7 Medical Costs$1,672$25 For patients discharged home, the daily medical costs for medication, laboratory tests, and dressing supplies are the same as in the hospital inpatient setting. However, general floor costs are eliminated and professional fees are reduced to $7 per day. The estimated daily cost for home discharge was determined to be $25 per day. Table 2 Summation of Costs Associated with TLC-II Driver Expenses Continuous Hospital Stay Discharge Home w/ TLC-II Purchase Discharge Home w/ TLC-II Rental Medical Cost$1,672/day$25/day Cost of TLC-II$0$150,000$12,500/month Home discharge with the purchase ($150,000) or rental ($12,500) of the TLC-II Portable Driver observed much higher initial cost than the cost of a hospital inpatient stay. However, as the cost points were projected over time, the cost of the hospital inpatient stay climbed much more rapidly than the cost of home discharge. RESULTS OBJECTIVES The cost of continued hospital inpatient stay equaled the cost of home discharge after 91.1 ($152,280) and 7.6 ($12,690) days of bridging for the TLC-II Portable Driver purchase and rental scenario respectively. The cost of a hospital inpatient stay for bridging days greater than 91.1 in a purchase scenario and 7.6 in a rental scenario, rose much faster than cost of home discharge days BTT w/o discharge BTT w/ discharge (purchase) Figure 1 Bridge-to-Transplant Patient Path Figure 3 Inpatient vs. Home Discharge Costs Assuming TLC-II Purchase 7.6 days BTT w/o discharge BTT w/ discharge (rental) Figure 4 Inpatient vs. Home Discharge Costs Assuming TLC-II Rental CONCLUSIONS Home discharge with the TLC-II Portable Driver may incur lower costs than continued outpatient hospitalization if the bridging period is in a purchasing scenario over three months or if the bridging period is in a rental scenario over one week, both of which are within the typical bridging time frame. REFERENCES 1. DeRose JJ, Umana JP, Argenziano M, et al. Implantable left ventricular assist device provide an excellent outpatient bridge to transplant and recovery. J Am Coll Cardiol 1997;30: Morales DL, Catanese KA, Williams MR, et al. Six-year experience of caring for forty-four patients with a left ventricular assist device at home: safe, economical, necessary. J Thorac Cardiovasc Surg 2000;119: Research supported by Thoratec Corporation "Being able to go home lifted my spirits. I had more freedom and felt that I could get back to recovering at my own pace. I don't think I'd be here today without that experience. - Joe Mazurek, TLC-II Patient The compact 9.8 kg Thoratec TLC-II Portable Driver provides univentricular or biventricular support for short- to long-term use.